Table 3

IRS2 SNP and haplotype associations with breast cancer





Matching adjusteda
Multivariate adjustedb
SNP
Alleles
Cases
Controls
OR
(95% CI)
P valuec
OR
(95% CI)
P valuec

IRS2
rs9515118









G/G
386
404
1.00
(-)

1.00
(-)


G/C
201
201
1.06
(0.83–1.34)

1.07
(0.83–1.37)


C/C
28
23
1.28
(0.72–2.29)
0.43
1.28
(0.70–2.31)
0.40

G/C or C/C
229
224
1.08
(0.85–1.36)
0.54
1.09
(0.86–1.38)
0.49

rs4773082









T/T
157
205
1.00
(-)

1.00
(-)


T/C
327
299
1.43
(1.10–1.86)

1.46
(1.12–1.91)


C/C
156
146
1.40
(1.03–1.91)
0.024
1.31
(0.96–1.80)
0.07

T/C or C/C
483
445
1.42
(1.11–1.82)
0.005
1.41
(1.10–1.81)
0.007

rs2289046









A/A
275
248
1.00
(-)

1.00
(-)


A/G
245
284
0.78
(0.61–0.99)

0.79
(0.61–1.01)


G/G
32
57
0.51
(0.32–0.81)
0.0018
0.52
(0.32–0.84)
0.004

A/G or G/G
277
341
0.73
(0.58–0.92)
0.009
0.74
(0.58–0.94)
0.016

rs754204









C/C
155
198
1.00
(-)

1.00
(-)


C/T
328
315
1.33
(1.02–1.73)

1.32
(1.01–1.73)


T/T
159
142
1.43
(1.05–1.94)
0.022
1.32
(0.96–1.82)
0.07

C/T or T/T
487
457
1.36
(1.06–1.74)
0.015
1.32
(1.03–1.70)
0.03

rs7987237









C/C
470
491
1.00
(-)

1.00
(-)


C/T
156
149
1.10
(0.85–1.43)

1.17
(0.90–1.53)


T/T
15
11
1.50
(0.68–3.31)
0.27
1.56
(0.70–3.50)
0.13

C/T or T/T
171
160
1.13
(0.88–1.45)
0.35
1.20
(0.93–1.55)
0.17

rs12584136









C/C
579
588
1.00
(-)

1.00
(-)


C/A
54
56
0.98
(0.66–1.44)

0.96
(0.64–1.43)


A/A
4
3
1.31
(0.29–5.88)
0.96
1.44
(0.31–6.71)
0.98

C/A or A/A
58
59
0.99
(0.68–1.45)
0.97
0.98
(0.67–1.45)
0.93

rs9559648









C/C
269
306
1.00
(-)

1.00
(-)


C/T
304
268
1.29
(1.02–1.62)

1.30
(1.03–1.65)


T/T
66
73
1.02
(0.71–1.49)
0.27
0.97
(0.66–1.42)
0.34

C/T or T/T
370
341
1.23
(0.99–1.53)
0.07
1.23
(0.98–1.54)
0.07

rs9559654









G/G
301
317
1.00
(-)

1.00
(-)


G/A
248
250
1.05
(0.83–1.33)

1.05
(0.82–1.34)


A/A
67
59
1.19
(0.81–1.75)
0.39
1.19
(0.80–1.76)
0.40

G/A or A/A
315
309
1.07
(0.86–1.34)
0.52
1.08
(0.86–1.35)
0.52

rs7997595









C/C
434
453
1.00
(-)

1.00
(-)


C/G
161
170
0.99
(0.77–1.28)

1.02
(0.79–1.32)


G/G
19
9
2.24
(1.00–5.01)
0.34
2.31
(1.02–5.24)
0.23

C/G or G/G
180
179
1.05
(0.82–1.35)
0.68
1.09
(0.84–1.40)
0.50

rs7981705









C/C
435
470
1.00
(-)

1.00
(-)


C/T
190
164
1.25
(0.98–1.60)

1.17
(0.91–1.51)


T/T
17
19
0.99
(0.50–1.93)
0.16
0.90
(0.45–1.79)
0.43

C/T or T/T
207
183
1.23
(0.97–1.56)
0.09
1.14
(0.89–1.46)
0.29

rs4773092









G/G
152
170
1.00
(-)

1.00
(-)


G/A
333
303
1.24
(0.95–1.62)

1.21
(0.92–1.60)


A/A
132
118
1.28
(0.92–1.78)
0.12
1.30
(0.93–1.82)
0.11

G/A or A/A
465
421
1.25
(0.97–1.62)
0.08
1.24
(0.95–1.61)
0.11

Haplotypes of rs4773082, rs2289046, and rs754204
CAT
296.8
273.2
1.00
-

1.00
-


TGC
188.8
227.4
0.74
(0.62–0.90)
0.0018
0.76
(0.63–0.92)
0.0050

TAC
107.3
104.6
0.99
(0.78–1.24)
0.89
1.04
(0.82–1.32)
0.75

Other groups
52.2
49.9
0.98
(0.72–1.33)
0.88
0.96
(0.70–1.32)
0.80




Global P value = 0.015
Global P value = 0.030

aAdjusted for race, birth date, and blood draw date. bAdjusted for race, birth date, blood draw date, adult weight change, breast cysts, family history of breast cancer, and hormone replacement therapy use. cFor IRS2 P values are provided for the log-additive model, and the dominant model; for Haplotypes of rs4773082, rs2289046, and rs754204, haplotype P values are compared with the most common haplotype. CI, confidence interval; IRS2, insulin receptor substrate 2 gene; OR, odds ratio.

Feigelson et al. Breast Cancer Research 2008 10:R57   doi:10.1186/bcr2114